1. U.S. will impose 100% tariffs on patented pharmaceuticals unless U.S. plants are built. 2. This policy may drastically impact pharmaceutical companies' supply chains and pricing.
Tariffs could favor domestic manufacturers while raising costs for imported drugs. Historically, similar tariffs have bolstered U.S. companies like Pfizer and AbbVie.
The tariffs will significantly affect pricing and competitive landscape, impacting XPH's holdings directly.
Immediate impact from tariffs on pricing and supply chains is expected to occur within months. Long-term effects depend on manufacturers' investments in U.S. facilities.